Alector presents results from first-in-human phase 1 study of al101 for the treatment of neurodegenerative diseases

Al101 is being developed to elevate progranulin (pgrn) levels with dosing regimens to be optimized for larger indications such as alzheimer's disease

ALEC Ratings Summary

ALEC Quant Ranking